Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2014
Bone-anchored hearing device placement with translabyrinthine tumor removal.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McRackan Theodore R, Goddard John C, Wilkinson Eric P, Slattery William H, Brackmann Derald E
Аннотация
OBJECTIVE: Translabyrinthine resection of intracranial tumors results in single-sided deafness, which can be treated by surgical and nonsurgical means. Here we describe the first series examining complication and device usage rates among patients receiving a surgically implanted bone-anchored hearing device (BAHD) at the time of translabyrinthine tumor removal.
STUDY DESIGN: Case series with chart review.
SETTING: Private tertiary neurotologic referral center.
PATIENTS: Patients (N = 154) undergoing concurrent BAHD placement and translabyrinthine tumor resection.
INTERVENTION: Concurrent BAHD placement and translabyrinthine tumor removal.
MAIN OUTCOME MEASURES: Postoperative complication rates and BAHD usage.
RESULTS: Of the 154 patients, 121 (78.6%) had no device-related complications. The most common device-related complications were skin overgrowth (8.4%), acute infection (5.2%), and chronic infection (3.2%). The overall and specific complication rates did not differ from published BAHD complication rates. One patient (0.6%) developed a cerebrospinal leak through the surgical site for the device. At the time of last follow-up (mean, 39.8 months), 151 patients (95.0%) were still using their devices.
CONCLUSION: Patients undergoing concurrent translabyrinthine tumor removal and BAHD placement exhibit similar device-related complication profiles as patients undergoing standard device placement. Based on these outcomes and the high long-term usage rates, BAHD insertion at the time of translabyrinthine intracranial surgery can be considered a safe and useful procedure.
STUDY DESIGN: Case series with chart review.
SETTING: Private tertiary neurotologic referral center.
PATIENTS: Patients (N = 154) undergoing concurrent BAHD placement and translabyrinthine tumor resection.
INTERVENTION: Concurrent BAHD placement and translabyrinthine tumor removal.
MAIN OUTCOME MEASURES: Postoperative complication rates and BAHD usage.
RESULTS: Of the 154 patients, 121 (78.6%) had no device-related complications. The most common device-related complications were skin overgrowth (8.4%), acute infection (5.2%), and chronic infection (3.2%). The overall and specific complication rates did not differ from published BAHD complication rates. One patient (0.6%) developed a cerebrospinal leak through the surgical site for the device. At the time of last follow-up (mean, 39.8 months), 151 patients (95.0%) were still using their devices.
CONCLUSION: Patients undergoing concurrent translabyrinthine tumor removal and BAHD placement exhibit similar device-related complication profiles as patients undergoing standard device placement. Based on these outcomes and the high long-term usage rates, BAHD insertion at the time of translabyrinthine intracranial surgery can be considered a safe and useful procedure.